Breaking News

Sanofi to Acquire Translate Bio for $3.2B

Upgrades drug formulation capabilities and accelerates development of licensed programs in vaccines and potential to explore other therapeutic areas.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Sanofi has entered into a definitive agreement to acquire Translate Bio, a clinical-stage mRNA therapeutics company, in a transaction valued at approximately $3.2 billion. Subject to customary closing conditions, the acquisition is expected to be completed in 3Q021. In June 2018, Sanofi and Translate Bio entered a collaboration and exclusive license agreement to develop mRNA vaccines which was further expanded in 2020 to address current and future infectious diseases. There are two ongoing mR...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters